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HIV infects macrophages and microglia in the central nervous system (CNS). Mechanisms that enhance HIV macrophage/microglial tropism
are not well understood. Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked
glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-
associated dementia (HAD) compared with non-HAD patients. D386 enhances HIV entry and replication in macrophages but not in microglia or
peripheral blood mononuclear cells, possibly due to differential glycosylation in these cell types. A D386N mutation in the UK1br Env, which
restores the N-linked glycan site, reduced neutralization sensitivity to the IgG1b12 (b12) monoclonal antibody, which recognizes a conserved
neutralization epitope that overlaps the CD4 binding site. Molecular modeling suggested that loss of the glycan at position 386 increases exposure
of the CD4 and b12 binding sites on gp120. Loss of a glycan at 386 was more frequent in Envs from HAD patients (26%; n=185) compared with
non-HAD patients (7%; n=99; pb0.001). The most significant association of these Env variants with HAD was in blood or lymphoid tissue
rather than brain. These findings suggest that increased exposure of the b12 epitope overlapping the CD4 binding site via elimination of a glycan
at position 386 is associated with enhanced HIV macrophage tropism, and provide evidence that determinants of macrophage and microglia
tropism are overlapping but distinct.
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GlycosylationIntroduction
Human immunodeficiency virus type 1 (HIV) infects macro-
phages and microglia in the central nervous system (CNS) and
causes HIV-associated dementia (HAD) or milder forms of
neurocognitive impairment (minor cognitive motor disorder
(MCMD)) in 10–20% of patients with AIDS (Gonzalez-
Scarano and Martin-Garcia, 2005; Kaul et al., 2001, 2005;
McArthur et al., 2003; Sacktor et al., 2002). Highly active anti-⁎ Corresponding author. Mailing address: Dana-Farber Cancer Institute, JFB
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doi:10.1016/j.virol.2007.05.029retroviral therapy (HAART) has reduced the incidence of HAD
(d'Arminio Monforte et al., 2004; Dore et al., 1999; Sacktor et
al., 2001, 2002), but most current antiviral drugs have relatively
poor CNS penetration and the prevalence of MCMD has
increased as HIV-infected patients survive for longer times on
anti-retroviral therapies (Dore et al., 2003; McArthur et al.,
2003; Neuenburg et al., 2002; Valcour et al., 2004). Thus,
neurological disease continues to be a significant complication
of HIV infection.
HIV variants in brain are genetically distinct from those in
lymphoid tissues and other organs, and sequences in the viral
envelope glycoprotein (Env) have been associated with brain
compartmentalization (Dunfee et al., 2006; Gartner et al., 1997;
223R.L. Dunfee et al. / Virology 367 (2007) 222–234Korber et al., 1994; Morris et al., 1999; Ohagen et al., 2003;
Power et al., 1995; Shapshak et al., 1999; Wang et al., 2001).
Furthermore, brain-derived Envs from HAD and non-HAD
AIDS patients are genetically and biologically distinct (Power et
al., 1994, 1998; Shah et al., 2006; Shapshak et al., 1999; Smit et
al., 2001). The capacity of HIV or simian immunodeficiency
virus (SIV) strains to replicate efficiently in macrophages has
been correlated with increased neurotropism (defined here as
the ability to replicate in microglia) (Ghorpade et al., 1998;
Gorry et al., 2001; Li et al., 1999; Peters et al., 2004; Sharma et
al., 1992; Wang et al., 2001), and may also be linked to
progression of HIV/SIV disease (Desrosiers et al., 1991; Gray et
al., 2005; Mori et al., 1992). However, mechanisms that
enhance HIV replication in macrophages in the CNS and other
macrophage-rich tissues such as lung, colon, and bone marrow
are not well understood.
HIV Env, which is organized into trimers on virions, consists
of the gp120 surface and gp41 transmembrane subunits. HIV
entry into cells is initiated by interaction between gp120 and
CD4, which induces a conformational change in gp120 that
exposes the coreceptor binding site (Doms, 2000). The
interaction of CD4-bound gp120 with the coreceptor triggers
a conformational change in gp120, which leads to structural
rearrangements in gp41 that enable fusion and virus entry.
CCR5, the primary coreceptor used for infection of macro-
phages and microglia (Albright et al., 1999; Ghorpade et al.,
1998; He et al., 1997; Li et al., 1999), is the coreceptor used by
most viruses isolated from brain (Albright et al., 1999; Gorry et
al., 2001; He et al., 1997; Li et al., 1999; Smit et al., 2001).
However, CCR5 usage is neither necessary nor sufficient for
neurotropism (Gorry et al., 2001; Yi et al., 2003). Tissue
macrophages and brain microglia express lower cell surface
levels of CD4 than CD4+ T cells in peripheral blood (Lewin et
al., 1996; Wang et al., 2002). HIV Envs with enhanced tropism
for macrophages/microglia have an increased capacity to
mediate fusion with cells expressing low levels of CD4 and
CCR5, suggesting that reduced dependence on CD4/CCR5
levels may enhance viral replication preferentially in the CNS
(Gorry et al., 2002; Gray et al., 2005; Martin et al., 2001; Peters
et al., 2004). We previously identified an HIV Env variant
associated with brain infection and HAD, N283 in the C2 region
of gp120, that increases gp120 affinity for CD4, enhancing the
capacity of HIV Envs to use low levels of CD4 for virus entry
and increasing viral tropism for macrophages and microglia
(Dunfee et al., 2006). However, additional mechanisms by
which HIV acquires an enhanced capacity to enter cells when
receptor levels are low are unclear.
The gp120 surface subunit of HIV Env is heavily glyco-
sylated (Leonard et al., 1990), resulting in occlusion of receptor
binding sites and epitopes for neutralizing antibodies (Kwong et
al., 1998; Wyatt et al., 1998). The HIV Clade B consensus
gp120 amino acid sequence contains 26 motifs for attachment
of N-linked glycans (NXS/T, where X is any amino acid except
proline). Amino acid variants that result in the loss of N-linked
glycosylation sites in the V1/V2 or V4 regions of HIV or SIV
Envs can facilitate infection of cells expressing little or no CD4
(Edwards et al., 2001; Hoffman et al., 1999; Kolchinsky et al.,2001; Puffer et al., 2002). Furthermore, studies of pathogenic
SIV and chimeric simian–human immunodeficiency virus
(SHIV) infections in rhesus macaques demonstrated that
macrophage tropism was associated with loss of conserved N-
linked glycosylation sites in Env (Igarashi et al., 2003; Puffer et
al., 2002). Whether loss of particular N-linked glycosylation
sites in HIV/SIV Envs enhances viral replication in the brain in
vivo remains unknown.
To investigate mechanisms by which HIVacquires enhanced
tropism for macrophages and microglia, we analyzed sequences
of brain-derived HIV Envs from 2 patients with HAD for
changes in N-linked glycosylation sites and identified an amino
acid variant, Asp 386 (D386), that eliminates an NXS/T motif at
position 386 in the V4 variable region of HIV gp120. D386
preferentially enhances viral entry and replication in macro-
phages but not microglia or peripheral blood mononuclear cells
(PBMC), possibly due to differential N-linked glycosylation in
these cell types. Restoring the glycan at 386 increases resistance
to neutralizing antibody IgG1b12 (b12), which recognizes a
conserved epitope that overlaps the CD4 binding site. Mole-
cular modeling suggested that loss of the glycan at position 386
increases exposure of the CD4 and b12 binding sites on gp120.
Loss of a glycan at 386 was significantly more frequent in Envs
from HAD patients compared with non-HAD patients. These
findings suggest that increased exposure of the b12 epitope
overlapping the CD4 binding site via elimination of a glycan at
position 386 enhances HIV macrophage tropism, and provide
evidence that determinants of macrophage and microglia tro-
pism are overlapping but distinct.
Results
Loss of a potential N-linked glycosylation site at position 386
in the V4 region in brain Envs from patients with HAD
Recently, we cloned and characterized HIV Envs from AIDS
patients with HAD and showed that Envs with reduced
dependence on CD4 and CCR5 levels are more frequent in
brain compared to lymphoid tissues (Thomas et al., 2007),
suggesting that viral adaptation for replication in the CNS
selects for variants with an enhanced capacity to enter cells
expressing low levels of receptors. To investigate mechanisms
by which neurotropic Envs acquire the ability to use low CD4,
we analyzed 23 full-length Env amino acid sequences from
HAD patients MACS2 and UK1 (6 Envs cloned from viral
isolates and 17 Envs cloned directly from brain and lymphoid
tissues; Gorry et al., 2002; Thomas et al., 2007) for variability in
N-linked glycosylation motifs (NXS/T, where X is any amino
acid except proline) that might affect exposure of the CD4
binding site. 10/17 brain-derived Envs had an Asp at position
386 in the V4 region, which resulted in elimination of a
potential N-linked glycosylation site relative to the Clade B
consensus. In contrast, 6/6 lymphoid-derived Envs had an intact
N-linked glycosylation site at this position (Fig. 1A). The
frequency of D386 was similar in Envs with low versus high
CD4 dependence (6/13 and 4/10, respectively). These results
suggest that D386 in the V4 region, which results in loss of a
Fig. 1. D386 is associated with brain-derived Envs from 2 HAD patients and has a minor effect on reduced CD4 dependence. (A) Amino acid sequences from the V4
region of gp120 from 2 HAD patients were obtained from published studies (Gorry et al., 2002; Thomas et al., 2007) and aligned using Clustal X. Potential N-linked
glycosylation sites are highlighted in gray. Sequences are numbered relative to the HXB2 reference sequence. Sequence names are notated as follows: br, brain-
derived; sp, spleen-derived. The number in parentheses represents the number of Env clones with each sequence. Dots represent residues identical to the Clade B
consensus sequence, and dashes represent gaps. (B) Lysates from 293Tcells transfected with UK1br wild-type or D386N mutant Envs were incubated with 0.01 μg/ml
trypsin for 2 h at 37 °C and analyzed by Western blotting with anti-gp120. (C) Cf2-Luc cells expressing different levels of CD4 and high CCR5 were mixed with 293T
cells expressing UK1br wild-type or D386N mutant Envs in cell–cell fusion assays (left) or infected with recombinant viruses expressing wild-type or mutant Envs in
entry assays (right). Cells were lysed after 8–12 h incubation or 48 h post-infection, respectively, and analyzed for luciferase activity. Data were normalized to
luciferase activity of the wild-type Env on cells expressing high CD4 and are expressed as means of duplicate wells from a single experiment. Error bars represent
standard deviations. Data are representative of 3 independent experiments.
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compared to lymphoid Envs from two HAD patients.
D386 makes a minor contribution to reduced CD4 dependence
To investigate whether D386 influences the capacity of
Envs to use low CD4, we constructed a D386N mutant in
UK1br15, a neurotropic Env that efficiently uses low levels of
CD4 to mediate fusion and entry (Dunfee et al., 2006; Gorry et
al., 2002). Hereafter, this Env is referred to as UK1br. To
determine if the D386N mutation, which restores a NXS/T
motif, resulted in a functional glycosylation site, UK1br wild-
type and D386N mutant Envs were analyzed by partial tryptic
digestion of 293T cell lysates. Trypsin-digested fragments of
UK1br D386N Env migrated more slowly in SDS-PAGE gels
compared to wild-type Env fragments, consistent with an
additional ∼2 kDa N-linked glycan relative to wild-type Env
(Fig. 1B). The D386N mutation in UK1br Env resulted in a
minor reduction in virus entry at all levels of CD4 (Fig. 1C).The magnitude of this effect was less than that of the N283T
mutation in UK1br Env, which significantly decreased virus
entry into cells expressing low levels of CD4 (Dunfee et al.,
2006). These data suggest that loss of a glycan at position 386
of UK1br results in a minor enhancement of virus entry at all
CD4 concentrations.
D386 preferentially enhances macrophage tropism
To determine if D386 influences macrophage and/or
microglia tropism, we cloned UK1br wild-type or D386N
mutant Envs into pNL4-3 and infected PBMC, monocyte-
derived macrophages (MDM), or microglia in primary human
brain cultures. Viruses expressing wild-type or mutant Envs had
similar replication kinetics and cytopathic effects in PBMC
(n=4 donors; Fig. 2A) and microglia in primary brain cultures
(n=4 of 5 donors; Fig. 2C and data not shown). In contrast, the
D386N mutant virus had delayed replication kinetics and
reduced syncytia formation in MDM (n=4 donors; Fig. 2B),
Fig. 2. Replication kinetics and cytopathic effects of viruses expressing UK1br wild-type and D386N mutant Envs in PBMC,MDM, and microglia. PBMC (A), MDM
(B), and microglia in primary human brain cultures (C) were infected as described in Materials and methods. Supernatants were collected every 3–7 days and
replication was monitored by p24 ELISA. Results shown are from triplicate samples. Error bars represent standard deviations. Data are representative of independent
experiments in 4 different donors per cell type. Photographs were taken at 14 (PBMC and MDM) or 28 (microglia) days post-infection at a 200× magnification.
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we described previously (Dunfee et al., 2006). These results
suggest that D386, or the loss of a glycan at position 386,
preferentially enhances UK1br tropism for macrophages.
To investigate whether D386 enhances macrophage tropism
in other brain-derived Envs, we used site-directed mutagenesis
to introduce N386D mutations in JRFL and YU2, well-
characterized, macrophage-tropic Envs from brain tissues of
HAD patients (Li et al., 1991; O'Brien et al., 1990), and in
UK1fl2–15 and UK1bg4–13, Envs cloned directly from the
brain of patient UK1 that enter MDM at high and intermediate
levels, respectively, compared with other UK1 Envs (Thomas et
al., 2007). We also introduced a D386N mutation in
MACS2br13, a brain-derived Env from patient MACS2 with
high CD4 dependence (Gorry et al., 2002) (Fig. 3A). Wild-type
and mutant Envs were expressed and processed to gp120 at
similar levels, and the loss or gain of an N-linked glycan was
suggested by slight differences in mobility in SDS-PAGE gels
compared to wild-type Envs (Fig. 3B). Consistent with our
previous results (Thomas et al., 2007), UK1 Envs had less
efficient processing of gp160 to gp120 compared to other Envs.MDM (from donor A in Fig. 2) and Cf2th cells expressing
different levels of CD4 and CCR5 were infected with luciferase
reporter viruses pseudotyped with wild-type and mutant Envs.
In JRFL Env, a N386D change increased virus entry to a similar
extent in MDM and Cf2th cells (50% and 58%, respectively). A
N386D mutation in UK1fl2–15 Env decreased the ability to
enter MDM by 37%, but had no effect on entry in Cf2th cells
(Fig. 3C). Thus, D386 does not preferentially enhance
macrophage tropism in these highly macrophage-tropic Envs
(O'Brien et al., 1990; Thomas et al., 2007). In contrast to these
results, in YU2 and UK1bg4–13 Envs, a N386D change
increased virus entry in MDM by 200% and 450%, respectively,
compared to wild-type (p=0.008 and 0.049, respectively,
Student's t-test), but did not increase entry in Cf2th cells
(p=0.14 and 0.27, respectively) (Fig. 3C). A reciprocal D386N
change in MACS2br13 Env resulted in a 65% decrease in the
ability to infect MDM compared to the wild-type Env
(p=0.027), but did not have a significant effect on entry in
Cf2th cells (p=0.79) (Fig. 3D). Collectively, Envs with D386
had an increased capacity to enter macrophages and Cf2th cells
compared to Envs with N386 (p=0.014, Student's t-test, n=10
Fig. 3. D386 in Envs with low or intermediate macrophage-tropism increases virus entry into macrophages. (A) Amino acid sequences from the V4 region of gp120 of
brain-derived Envs used in this study were obtained from Genbank (JRFL and YU2, accession numbers U63632 and M93258, respectively) or published studies
(Gorry et al., 2002; Thomas et al., 2007) and aligned using Clustal X. Potential N-linked glycosylation sites are highlighted in gray. Sequences are numbered relative to
the HXB2 reference sequence. Dots represent residues identical to the Clade B consensus sequence, and dashes represent gaps. (B) 293T cells expressing wild-type or
mutant Envs were lysed and analyzed by Western blotting with anti-gp120. The positions of gp160 and gp120 are indicated on the right. (C, D) Cf2th cells expressing
different levels of CD4 and CCR5 or MDM were infected with luciferase-expressing reporter viruses pseudotyped with wild-type, N386D mutant (C), or D386N
mutant (D) Envs. Cells were lysed 48 to 72 h postinfection and analyzed for luciferase activity. Data were normalized to the amount of luciferase activity of the wild-
type Env on cells expressing high CD4/CCR5 or on MDM. Results shown are from duplicate (Cf2th) or triplicate (MDM) samples. Error bars represent standard
deviations. ∗, pb0.05, ∗∗, pb0.01, Student's t-test.
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linked glycan at position 386 enhances HIV entry in macro-
phages and transfected Cf2th cells in 5/6 Envs from 4 HADpatients, and that D386 preferentially enhances macrophage
tropism in 4/6 Envs from 3 HAD patients (YU2, UK1br,
UK1bg4–13, and MACS2br13).
Table 1
Neutralization of UK1br wild-type and D386N mutant viruses by mAbs and
CD4-IgG2
mAb Epitope UK1br UK1br D386N
b12 CD4 binding site 0.04 0.31
F105 CD4 binding site N20 N20
17b CD4-induced N20 N20
2G12 Outer domain glycans N20 N20
2F5 gp41 2.87 3.11
CD4-IgG2 CD4 binding site 0.92 1.78
mAb or CD4-IgG2 concentration (μg/ml) at which luciferase expression was
reduced by 50% compared to infection in the absence of mAb (IC50).
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compared to microglia or PBMC
HIV Envs expressed in infected macrophage and PBMC
cultures are differentially glycosylated (Lin et al., 2003; Willey
et al., 1996). Thus, one possible explanation for the different
effects of the UK1br D386N mutation on replication in PBMC,
MDM, and microglia is differential N-linked glycosylation of
Envs produced in these cell types. To investigate glycosylation
of UK1br Env produced in primary cells, we purified virions
from supernatants of infected PBMC, MDM, and primary brain
cultures and analyzed virion-associated gp120 by Western
blotting. Consistent with previous studies (Lin et al., 2003;
Willey et al., 1996), UK1br Envs produced in MDM had
decreased mobility and a more diffuse migration pattern in
SDS-PAGE gels compared to Envs produced in PBMC (Fig. 4).
Unexpectedly, Envs produced in MDM migrated more slowly
and had a more diffuse pattern in SDS-PAGE gels than Envs
produced in microglia (Fig. 4). Together with previous studies
demonstrating that differences in mobility of MDM- and
PBMC-derived Envs were due to glycosylation (Lin et al.,
2003; Willey et al., 1996), these results suggest that UK1br
Envs are more highly glycosylated when expressed in MDM
compared to PBMC or microglia. These findings are consistent
with the possibility that differences in replication of the UK1br
wild-type and D386N mutant viruses in these primary cell types
are due to differential N-linked glycosylation.
D386 influences sensitivity of UK1br to neutralization by the
CD4 binding site monoclonal antibody b12
Env glycosylation is important for maintaining structure and
shielding conserved structural epitopes from neutralizing
antibodies (Burton et al., 2004). To investigate whether the
loss of a glycan at position 386 influences sensitivity to
neutralizing antibodies, we analyzed neutralization of virusesFig. 4. Western blot of virions from infected microglia, MDM, and PBMC.
Virions from infected microglia, MDM, or PBMC cultures were purified by
high-speed centrifugation on a sucrose cushion as described in Materials and
methods, lysed, and analyzed by Western blotting with anti-gp120 or anti-p24.
The positions of gp120, p24, and the Gag precursor proteins p55 and p41 are
indicated on the left.containing wild-type and D386N mutant UK1br Envs by a
panel of monoclonal antibodies (mAbs) (summarized in Table
1). We previously demonstrated that the UK1-br primary isolate
is sensitive to neutralizing antibody b12, which maps to an
epitope that overlaps the CD4 binding site, and CD4-IgG2
(Gorry et al., 2002). A D386N change resulted in an 8-fold
increase in resistance to neutralization by b12 and a 2-fold
increase in resistance to CD4-IgG2 (Table 1 and Fig. 5). In
contrast, there was no difference in sensitivity of the wild-type
or D386N mutant UK1br viruses to neutralization by mAbs
directed against other epitopes in gp120 and gp41 (Table 1).
Together, these results suggest that D386 influences sensitivity
of UK1br Env to neutralization by antibody b12, and raise the
possibility that changes in amino acid sequence at this position
may affect the conformation and/or exposure of the CD4 and
mAb b12 binding sites.
Loss of a glycan at 386 increases exposure of the CD4 and
mAb b12 binding sites
To investigate the mechanism by which changes at position
386 might affect the CD4 binding site, we used Swiss PDB
Viewer (http://ca.expasy.org/spdbv) to model the amino acid at
this position on the YU2 gp120-CD4-17b crystal structure
(1G9N) (Kwong et al., 1998). The HIV Clade B consensusFig. 5. Neutralization of UK1br wild-type and D386N mutant viruses by mAb
b12. Recombinant viruses expressing UK1br wild-type or D386N mutant Envs
were incubated with mAb b12 for 1 h and then used to infect Cf2-Luc cells
expressing high levels of CD4 and CCR5. Cells were lysed 36 h postinfection
and analyzed for luciferase activity. Data are normalized to the amount of
luciferase activity in cells infected with virus in the absence of b12 and
expressed as the mean of duplicate samples. Error bars represent standard
deviations. Results are representative of 4 independent experiments.
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the highly glycosylated outer domain of gp120 (Kwong et al.,
1998; Wyatt et al., 1998), proximal to the base of the V3 loop
and the CCR5 binding site, and ∼12 Å from the CD4 binding
site. Introducing an N386D change in the structural model did
not alter predicted interactions with amino acids that contact
CD4 (data not shown). Previous studies demonstrated that N386
in monomeric gp120 produced in CHO cells is glycosylated
with a high mannose group (Leonard et al., 1990). To better
understand how a glycan at this position might affect the CD4
binding site, we aligned the N-acetylglucosamine (NAG)
attached to N386 in the YU2 crystal structure with the first
NAG of a high mannose group from the crystal structure of HIV
mAb 2G12 bound to its Man9GlcNAc2 epitope (1OP5)
(Calarese et al., 2003). The addition of the mannose group
resulted in a modified N386 in which the carbohydrate side
chains were only ∼7 Å from CD4, partially occluding the CD4
binding site (Fig. 6B). Together with previous studies
demonstrating that removal of the glycan at position 386 affects
the conformation of surrounding carbohydrate chains (Scanlan
et al., 2002), the structural modeling data suggest that removalFig. 6. Structural modeling of position 386 in Envs bound to CD4 or mAb b12. Swiss
YU2 gp120-CD4-17b CD4i Ab crystal structure (1G9N) (Kwong et al., 1998) (A, B) o
Blue, gp120. Yellow, CD4. Green, 17b CD4i Ab (A, B) or mAb b12 (C, D). Orange
crystal structure. Position 386 is ∼12 Å from the CD4 binding site. (B) The N-ace
mannose group (Man9GlcNAc2) derived from the crystal structure of mAb 2G12 bou
of gp120 with intact glycosylation at position 386. (C) N386 and the attached NAG m
an N386D change in HXB2, which results in elimination of the NAG but retains thof this N-linked glycosylation site may directly or indirectly
increase exposure of the CD4 binding site.
To investigate the mechanism by which D386 might enhance
sensitivity to mAb b12, we modeled the N386D change on the
recently described HXB2 gp120-b12 crystal structure (Zhou et
al., 2007). N386 and the attached NAG contact Trp 100 (W100)
of the heavy chain of b12, with the amino acid side chains
stacking together (Fig. 6C) and a hydrogen bond between the
backbone of W100 and the NAG (data not shown) (Zhou et al.,
2007). Modeling a D386 change in the structure eliminated the
hydrogen bond betweenW100 and the NAG of N386, but D386
and W100 of b12 side chains had a similar stacking confor-
mation as the wild-type N386 (Fig. 6D). Thus, a D386N change
would be predicted to enhance b12 binding and neutralization
by restoring the hydrogen bond between the NAG on N386 and
the mAb heavy chain. However, a D386N mutation in UK1br
Env had the opposite effect and increased resistance to
neutralization by b12. These data suggest that a mechanism
other than direct binding of b12 to D386, such as increased
exposure of the b12 epitope, underlies the increase in b12
neutralization sensitivity mediated by D386.PDB Viewer was used to model changes at position 386 on the V4 region of the
r the HXB2 gp120-mAb b12 crystal structure (2NY7) (Zhou et al., 2007) (C, D).
, position 386. White, carbohydrate moieties. (A) Location of N386 in the YU2
tylglucosamine (NAG) attached to N386 was aligned with NAG1 from a high
nd to its carbohydrate epitope (1OP5) (Calarese et al., 2003) to produce a model
ake contacts with W100 of mAb b12. (D) Swiss PDB Viewer was used to model
e conformation of the b12 W100 and Env amino acid 386 side chains.
Table 3
Loss of an N-linked glycosylation site at position 386 is associated with HADa
Comparison Amino acid at 386 Glycosylation
site at 386
Nb D K S Present Absent
By tissue (22 patients)
Brain (n=152) 0.83 c 0.14 0.03 0 0.82 0.18
Lymphoid (n=132) 0.82 0.10 0.04 0.04 0.80 0.20
By disease
HAD (13 patients)
Total (n=185) 0.76 0.16∗ 0.05 0.03 0.74 0.26∗∗
Brain (n=103) 0.79 0.16 0.04 0.01 0.78 0.22
Lymphoid (n=82) 0.73 0.15∗ 0.06 0.06 0.70 0.30∗∗
Non-HAD (9 patients)
Total (n=99) 0.95 0.05∗ 0 0 0.93 0.07∗∗
Brain (n=49) 0.92 0.08 0 0 0.90 0.10
Lymphoid (n=50) 0.98 0.02∗ 0 0 0.96 0.04∗∗
∗, pb0.05. ∗∗, pb0.001. p values calculated using Fisher's exact test.
a Sequences were obtained from published studies (Dunfee et al., 2006;
Gartner et al., 1997; Gorry et al., 2002; Korber et al., 1994; Liu et al., 2000;
Martin-Garcia et al., 2006; Ohagen et al., 2003; Pang et al., 1991; Shapshak
et al., 1995; Thomas et al., 2007) and Genbank.
b N is the Clade B consensus residue.
c The frequency is calculated by dividing the number of sequences with each
amino acid variant or with or without the NXS/T glycosylation motif (where X
is any amino acid except proline) at position 386 by the total number of
sequences. Sequences were limited to 2 to 10 per patient.
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enhanced macrophage tropism
To investigate whether increased neutralization sensitivity to
mAb b12 is associated with enhanced macrophage tropism in a
larger data set, we tested b12 neutralization of viruses
expressing UK7br, ADA, or MACS2br13 Envs, and performed
a meta-analysis of these results together with b12 neutralization
data from 4 published studies (Binley et al., 2004; Gray et al.,
2005; Thomas et al., 2007; Wei et al., 2003) (Table 2). For this
analysis, we compiled results for HIV Envs or isolates that have
been well-characterized for their macrophage tropism (Collman
et al., 1989; Dunfee et al., 2006; Gray et al., 2005; Li et al.,
1991; O'Brien et al., 1990; Thomas et al., 2007). Highly
macrophage-tropic viruses had increased sensitivity to b12
neutralization (median 50% neutralization (IC50) 0.16 μg/ml,
n=10) compared to Envs with low or intermediate macrophage
tropism (median IC50 4.21 μg/ml, n=8) (p=0.0044, Mann–
Whitney test). Furthermore, 9 of 11 (82%) of Envs with b12
IC50≤2 μg/ml were highly macrophage-tropic, compared with
only 1 of 7 (14%) of Envs with b12 IC50N2 μg/ml (p=0.013,
Fisher's exact test). Thus, there is a significant association
between increased sensitivity to b12 neutralization and
enhanced macrophage tropism. In contrast, there was no
correlation between sensitivity to other gp120 mAbs and
enhanced macrophage tropism in this data set (Binley et al.,
2004; Gray et al., 2005; Thomas et al., 2007; Wei et al., 2003)
(Table 1). Viruses with Env variant D386 were sensitive to b12
neutralization (n=4, IC50 0.03 to 2.8 μg/ml), whereas viruses
with N386 had variable sensitivity to b12 neutralization (n=14,
IC50 0.03 to 25 μg/ml) (Table 2). Together, these findingsTable 2
Neutralization sensitivity of HIV-1 Envs and viral isolates with variable









UK1br High D 0.03
SF162 High N 0.03 Binley et al., 2004
JRFL High N 0.09 Binley et al., 2004
NB6 High D c b0.1 Gray et al., 2005
UK7br High N 0.16
NB2 High N c 0.16 Gray et al., 2005
BaL High N 0.19 Binley et al., 2004
ADA High N 0.91
NB7 High N c 2 Gray et al., 2005
NB8 High D c 2.8 Gray et al., 2005
MACS2br13 Intermediate D 0.48
YU2 Intermediate N 2.3 Wei et al., 2003
MACS2fl8–12 Intermediate N 5.22 Thomas et al., 2007
JRCSF Low N 0.16 Binley et al., 2004
NB25 Low Nc 3.2 Gray et al., 2005
NB27 Low Nc 7 Gray et al., 2005
NB24 Low Nc 12 Gray et al., 2005
NB23 Low Nc 25 Gray et al., 2005
a Data represents results of neutralization assays performed using cloned HIV
Envs except for BaL (viral quasispecies) and the data from Gray et al. (primary
isolates).
b μg/ml.
c J. Sterjovski and P. R. Gorry, unpublished data.suggest that increased exposure of the b12 epitope is associated
with enhanced tropism of HIV for macrophages. The influence
of the N-linked glycosylation site at position 386 on b12
neutralization sensitivity, however, is strain-dependent.
Loss of a glycan at position 386 is associated with dementia
in vivo
To determine if the loss of an N-linked glycan at position 386
is associated with brain infection or dementia in vivo, we
examined 284 matched brain- and blood- or lymphoid-derived
Envs from 22 patients in 10 published studies (Dunfee et al.,
2006; Gartner et al., 1997; Gorry et al., 2002; Korber et al., 1994;
Liu et al., 2000; Martin-Garcia et al., 2006; Ohagen et al., 2003;
Pang et al., 1991; Shapshak et al., 1995; Thomas et al., 2007).
D386 or another amino acid variant that results in loss of the
NXS/T motif at position 386 appeared in 18% of brain-derived
sequences (n=152) and 20% of blood or lymphoid-derived
sequences (n=132) (Table 3). Thus, loss of an N-linked glycan
at position 386 is not associated with brain compartmentaliza-
tion. To determine if loss of a glycan at this site is associated with
HAD in this data set, we compared sequences from HAD and
non-HAD patients. Amino acid variants that resulted in the loss
of the glycosylationmotif appeared in 26% of sequences from 13
HAD patients (n=185), compared to only 7% of sequences from
9 non-HAD patients (n=99) (Table 3). In contrast, variants that
eliminated any of the 4 other NXS/T motifs in the Clade B
consensus V4 region appeared at similar or lower frequencies in
HAD compared to non-HAD patients (data not shown). Thus,
the loss of an N-linked glycan at position 386 was significantly
associated with dementia (pb0.001, Fisher's exact test, with
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amino acid variants resulting in elimination of the NXS/T
motif appeared in 22% of brain-derived sequences from HAD
patients (n=103) compared to 10% from non-HAD patients
(n=49), the most significant association of these variants with
HAD was in the blood or lymphoid compartment. Amino acid
variants resulting in the loss of a glycosylation site at position
386 appeared in blood or lymphoid-derived Envs in 30% of
sequences from HAD patients (n=82) compared to only 4% of
sequences from non-HAD patients (n=50; pb0.001) (Table 3).
These results suggest that D386 and other variants that result in
elimination of an N-linked glycosylation site at position 386 are
associated with dementia in vivo.
Discussion
In this study, we demonstrated that D386 and other amino
acids that result in the loss of an N-linked glycosylation site in
the V4 region of HIV gp120 are more frequent in brain and
lymphoid Envs from HAD patients (26%, n=185) compared to
non-HAD patients (7%, n=99; pb0.001). D386 preferentially
enhances HIV tropism for macrophages but not microglia or
PBMC, possibly as a result of differential modification of N-
linked glycosylation motifs in these primary cell types. A
D386N mutation in UK1br Env increased resistance to b12
neutralization by 8-fold compared to wild-type. These results,
together with molecular modeling studies, suggest that loss of a
glycan at position 386 increases exposure of the CD4 binding
site. These findings also suggest an association between
exposure of the b12 epitope, which overlaps the CD4 binding
site, and enhanced HIV tropism for macrophages. Consistent
with this idea, increased b12 neutralization sensitivity is
associated with enhanced macrophage tropism of other Clade
B Envs as well (p=0.0044, Mann–Whitney test).
Molecular modeling with the D386 variant in the YU2
crystal structure (1G9N) (Kwong et al., 1998) suggests that
removal of the high mannose group attached to position 386,
which is located on the heavily glycosylated outer domain of
gp120, increases exposure of the CD4 binding site. Restoring
the N-glycan at 386 increased UK1br resistance to neutraliza-
tion by sCD4-Ig by only 2-fold, consistent with our finding that
a D386N mutation had only a minor effect on the capacity of
UK1br Envs to use low CD4. In contrast, the N283T mutation,
which influences gp120 affinity for CD4 but has no significant
effect on b12 neutralization (R. Dunfee and D. Gabuzda,
unpublished data), has a significant effect on virus entry into
cells expressing low CD4 (Dunfee et al., 2006). The observation
that UK1br D386N mutant virus was 8-fold more resistant to
neutralization by b12 than the wild-type virus was unexpected,
since molecular modeling with the HXB2 gp120-b12 crystal
predicted that a D386Nmutation would enhance b12 binding by
restoring interactions between the glycan at N386 and the mAb
heavy chain. The influence of this glycan on b12 sensitivity is
strain-dependent, however (Table 2). D386 may work coopera-
tively with changes in the V1/V2, C2, V3, and/or C3 regions,
since these regions also influence sensitivity to b12 neutraliza-
tion (Koch et al., 2003; Mo et al., 1997; Pugach et al., 2004).Alternatively, changes in glycan structure at position 386 could
affect the conformation and packing of other carbohydrates on
the outer domain of gp120 to modulate exposure of the CD4
and mAb b12 binding sites. The finding that loss of an N-linked
glycan at position 386 in an HXB2 Env adapted to use only
CXCR4 for entry enhanced sensitivity to neutralization by
HIV-infected patient sera (Edwards et al., 2001) provides
further evidence that changes at position 386 influence
exposure of the CD4 binding site and conserved neutralization
epitopes on gp120. Position 386 is located at the base of the V3
loop and proximal to the coreceptor binding site. Thus, changes
at this position may influence Env interactions with CCR5 as
well.
Brain macrophages and microglia are both derived from the
mononuclear phagocyte lineage, yet they differ in some
phenotypic and functional characteristics (Gonzalez-Scarano
and Martin-Garcia, 2005). Whether HIV tropism for macro-
phages and microglia is similar (Ghorpade et al., 1998; Gorry et
al., 2001), or overlapping but distinct (Strizki et al., 1996), has
been debated. The D386N mutation in UK1br decreased viral
entry and replication in macrophages but had no effect on viral
replication in microglia. In contrast, the N283 variant, which
increases gp120 affinity for CD4, enhances viral tropism for
both macrophages and microglia (Dunfee et al., 2006). MDM-
derived Envs migrated more slowly on SDS-PAGE gels than
microglia- or PBMC-derived Envs, consistent with increased
gp120 glycosylation. Thus, D386 may preferentially enhance
HIV replication in macrophages as a consequence of differential
N-linked glycosylation in these primary cell types.
The mechanism by which loss of an N-linked glycan at
position 386 contributes to enhanced tropism for macrophages,
but not PBMC or microglia, is unknown. Restoring the glyco-
sylation site with a D386Nmutation in UK1br Envs had a minor
effect on virus entry in Cf2th cells at all levels of CD4, raising
the possibility that D386 enhances Env interactions with CD4,
and/or CCR5, albeit to a minor extent. One possible explanation
for preferential enhancement of macrophage tropism by D386 is
differential glycosylation of the NXS/T motif at 386 in PBMC,
macrophages, and microglia. An alternative possibility is that
changes in glycosylation at position 386 influence Env
interactions with molecules important for initial attachment to
macrophages, such as DC-SIGN, macrophage mannose recep-
tor, syndecans, or other attachment factors (Binley et al., 2006;
Nguyen and Hildreth, 2003; Saphire et al., 2001). Further
studies are needed to investigate these possibilities.
The CNS has lower concentrations of neutralizing antibodies
compared to peripheral tissues (Goudsmit et al., 1987; Kaul et
al., 2001), and may therefore be a favorable environment for
replication and persistence of HIV variants with exposed
receptor binding sites. Most HIV-infected individuals do not
develop neurological dysfunction until after development of
immunosuppression and progression to AIDS. Loss of immune
control associated with disease progression is one possible
reason why HAD typically occurs only in the late stages of HIV
infection (Gonzalez-Scarano and Martin-Garcia, 2005). Van
Marle et al. (2002) demonstrated that sera from HAD patients
was less efficient at neutralizing HIV than sera from non-HAD
231R.L. Dunfee et al. / Virology 367 (2007) 222–234patients, suggesting that patients with HAD may have a
decreased ability to generate neutralizing antibodies. The
significantly higher frequency of D386, a viral variant that
enhances b12 neutralization sensitivity, in blood- and lymphoid-
derived Envs from HAD patients compared to non-HAD
patients, is consistent with the possibility that loss of a glycan at
386 may have evolved more readily in these individuals because
they have lower levels of neutralizing antibodies that target the
b12 epitope. In a longitudinal study of neutralizing antibody
responses, changes at positions 400–406 in the V4 region were
indicative of adaptive mutations selected by immune responses
(Wei et al., 2003). In our Env sequence data set, position 406
was the only N-linked glycosylation motif in the V4 region that
was eliminated at a significantly higher frequency in non-HAD
patients (49%, n=99) compared to HAD patients (26%,
n=185; pb0.001, Fisher's exact test, with Bonferroni correc-
tion for multiple comparisons) (data not shown). These
observations and the association between enhanced macrophage
tropism and increased exposure of the b12 epitope demonstrated
here and by others (Gray et al., 2005) raise the possibility that
macrophage-tropic strains may evolve more readily in indivi-
duals with low levels of neutralizing antibodies directed against
outer domain regions of Env.
The identification and characterization of the loss of an N-
linked glycan at position 386 in the V4 region of gp120 suggests
that increased exposure of the b12 epitope overlapping the CD4
binding site enhances HIV macrophage tropism, and provide
evidence that determinants of macrophage and microglia
tropism are overlapping but distinct. These findings also
provide insights that may facilitate development of immuno-
gens that elicit broadly neutralizing antibodies as well as




293T cells and canine thymocyte cell line Cf2th (Choe et al.,
1996) were cultured in DMEM medium supplemented with
10% (vol/vol) fetal bovine serum (FBS) and 100 μg/ml
penicillin and streptomycin. Cf2-Luc cells, which are derived
from Cf2th cells and stably express luciferase under control of
HIV-1 LTR (Etemad-Moghadam et al., 2000), were cultured in
medium supplemented with 0.7 mg/ml G418 (Mediatech,
Herndon, VA). Peripheral blood mononuclear cells (PBMC)
were isolated from the blood of healthy HIV-1-negative donors
as described (Gorry et al., 2001), stimulated with 2 μg/ml
phytohemagglutinin (PHA; Sigma, St. Louis, MO), and
cultured in RPMI 1640 medium supplemented with 10% (vol/
vol) FBS, 100 μg/ml penicillin and streptomycin, and 20 U/ml
interleukin-2 (Boehringer Mannheim, Germany). CD8+ T cells
were depleted with anti-CD8-conjugated magnetic beads
(Miltenyi Biotech, Auburn, CA). Monocyte-derived macro-
phages (MDM) were isolated from PBMC by plastic adherence
and cultured in RPMI 1640 medium supplemented with 10%
FBS, 100 μg/ml penicillin and streptomycin, and 10 ng/mlmacrophage colony stimulating factor (M-CSF; R&D Systems,
Minneapolis, MN) (Gorry et al., 2001). Primary human fetal
brain cultures containing a mixture of astrocytes, neurons, and
microglia were prepared and maintained in 48-well tissue
culture plates as described (Gorry et al., 2001, 2002) and
cultured in DMEM medium supplemented with 10% bovine
calf serum (HyClone, Logan, UT), 100 μg/ml penicillin and
streptomycin, 1 mM sodium pyruvate (Invitrogen, Carlsbad,
CA), and 10 ng/ml M-CSF.
Virus isolates, HIV Env cloning, and sequence analysis
Primary viruses MACS2-br and UK1-br were previously
isolated from autopsy brain tissues from AIDS patients with
HAD (Gorry et al., 2001). Env genes amplified from genomic
DNA extracted from PBMC on day 7 post-infection with these
primary isolates or from autopsy brain tissue and cloned into
pCR3.1 were described previously (Dunfee et al., 2006; Gorry
et al., 2002; Thomas et al., 2007). Env protein expression was
verified by Western blot with goat anti-gp120 (AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID,
NIH, Bethesda, MD) (Gorry et al., 2002). Sequences were
aligned using Clustal X. D386N and N386D mutant Env
plasmids were created by PCR-based mutagenesis and changes
were verified by DNA sequencing. Differences in migration of
UK1br wild-type and D386N mutant Envs on SDS-PAGE gels,
consistent with changes in glycosylation, were verified by
Western blot with goat anti-gp120 of 293T lysates incubated
with 0.01 μg/ml trypsin (Sigma, St. Louis, MO) for 2 h at 37 °C,
run on a 4–20% SDS-PAGE gradient gel, and analyzed by
Western blot with goat anti-gp120.
Fusion assays
293T cells were cotransfected with 15 μg of Env-expressing
plasmid and 2 μg of pLTR-Tat using calcium phosphate. Cf2-
Luc cells (Gorry et al., 2002) were cotransfected with different
amounts of pcDNA3-CD4 and pcDNA3-CCR5 as indicated
using Lipofectamine 2000 (Invitrogen). The total amount of
DNA in each transfection was normalized using pcDNA3.
2.5×104 293T cells and 2.5×105 Cf2-Luc cells were mixed in
48-well plates and incubated at 37 °C for 8 to 12 h. Cells were
lysed and assayed for luciferase activity. 293T cells cotrans-
fected with a nonfunctional Env (pSVIII-ΔKSenv) and pLTR-
Tat were used to determine background levels.
Entry assays
The KpnI to BamHI region of env was PCR amplified and
cloned into pNL4-3 to generate replication-competent chimeric
viruses (Ohagen et al., 2003). HIV luciferase reporter viruses
were generated by cotransfection of 293T cells with pNL4-
3env−luc, an HIV provirus with env deleted and nef replaced by
luciferase, and an Env-expressing plasmid as described (Gorry
et al., 2002). Cf2th or Cf2-Luc cells were cotransfected with
pcDNA3-CD4 and pcDNA3-CCR5 as above. Transfected cells
were infected with 104 3H cpm reverse transcriptase (RT) units
232 R.L. Dunfee et al. / Virology 367 (2007) 222–234of virus stock. Cells were lysed 48 to 60 h post-infection and
assayed for luciferase activity. MDM were prepared as above in
48-well plates and infected with 2×104 3H cpm RT units of
virus stock. Cells were lysed 6 days post-infection and assayed
for luciferase activity.
HIV replication kinetics
3×106 PBMC were prepared as described (Gorry et al.,
2001) and incubated with 5×104 3H cpm RT units of virus stock
for 3 h at 37 °C. MDM were prepared by plastic adherence as
described above in 24-well tissue culture plates, cultured in the
presence of M-CSF for 7 days prior to infection, and incubated
with 2×104 3H cpm RT units for 3 h at 37 °C. Primary human
fetal brain cultures containing a mixture of astrocytes, neurons,
and microglia were prepared and maintained in 48-well tissue
culture plates as described (Gorry et al., 2001, 2002) and
incubated with equivalent amounts of virus stock (104 3H cpm
RT units) for 16 h at 37 °C. 50% media changes were performed
every 3 to 7 days for 28 to 35 days. Virus replication was
monitored by p24 ELISA (Perkin Elmer, Boston, MA).
Virion preparation and Western blot
Virions were purified from cell culture supernatant of
infected PBMC, MDM, or primary human fetal brain cultures
by high-speed centrifugation on a 20% sucrose gradient and
resuspended in lysis buffer (1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 0.05 M Tris
hydrochloride buffer [pH 7.5], 0.15 M NaCl, 1 mM EDTA,
Complete protease inhibitor cocktail (Roche, Indianapolis, IN))
at a concentration of 1 ng p24 antigen/μl. Equivalent amounts of
virions were run on a 4–20% SDS-PAGE gradient gel, and
analyzed by Western blotting with goat anti-gp120 as above or
with rabbit anti-p24 (Abbott Laboratories, Abbott Park, IL).
Neutralization assays
Replication-competent chimeric virus stocks were incubated
with a range of concentrations of human monoclonal Abs
(mAbs), or CD4-IgG2 1 h prior to infection of Cf2-Luc cells
transiently expressing CD4 and CCR5. Cells were harvested
48 h post infection and assayed for luciferase activity. mAbs
b12 (Roben et al., 1994), 2G12 (Buchacher et al., 1994), and
2F5 (Buchacher et al., 1994; Purtscher et al., 1994) were
obtained from D. Burton and P. Parren, and H. Katinger (2G12
and 2F5), respectively, through the AIDS Research and
Reference Reagents Program. mAb 17b (Thali et al., 1993)
was kindly provided by J. Robinson. mAb F105 was kindly
provided byM. Posner and L. Cavacini. The plasmid expressing
CD4-IgG2 was kindly provided by M. Farzan.
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